PDF) A 24‐week multicentre, randomised, open‐label, parallel‐group study comparing the efficacy and safety of ixekizumab to fumaric acid esters and methotrexate in patients with moderate‐to‐severe plaque psoriasis naïve to systemic treatment
Schneider Electric Applauded by Frost & Sullivan for Decreasing Unplanned Downtimes/Outages and Carbon Footprint with Its Sustainable Switchgear